Clinical Trial Update: 601 Versus Ranibizumab in Patients With Pathological Myopic Choroidal Neovascularization (pmCNV) [Phase 2]

View source ↗

Summary

Phase 2 clinical trial comparing 601 versus Ranibizumab for pathological myopic choroidal neovascularization is ongoing with unknown status.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pathological Myopic Choroidal Neovascularization

Drugs mentioned

• 601
• Ranibizumab (ranibizumab)

Snippet

Sponsor: Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | Conditions: Pathological Myopic Choroidal Neovascularization | Phase 2 | Status: UNKNOWN